PL3636649T3 - Diaryle makrocykliczne jako modulatory kinaz białkowych - Google Patents
Diaryle makrocykliczne jako modulatory kinaz białkowychInfo
- Publication number
- PL3636649T3 PL3636649T3 PL19212110.1T PL19212110T PL3636649T3 PL 3636649 T3 PL3636649 T3 PL 3636649T3 PL 19212110 T PL19212110 T PL 19212110T PL 3636649 T3 PL3636649 T3 PL 3636649T3
- Authority
- PL
- Poland
- Prior art keywords
- modulators
- protein kinases
- macrocycles
- diaryl
- diaryl macrocycles
- Prior art date
Links
- -1 Diaryl macrocycles Chemical class 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931506P | 2014-01-24 | 2014-01-24 | |
| US201462049326P | 2014-09-11 | 2014-09-11 | |
| US201562106301P | 2015-01-22 | 2015-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3636649T3 true PL3636649T3 (pl) | 2024-05-06 |
Family
ID=53682127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19212110.1T PL3636649T3 (pl) | 2014-01-24 | 2015-01-23 | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| PL15740510T PL3097107T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| PL19169041.1T PL3572416T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15740510T PL3097107T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| PL19169041.1T PL3572416T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
Country Status (35)
| Country | Link |
|---|---|
| US (7) | US9714258B2 (fr) |
| EP (6) | EP3636650A1 (fr) |
| JP (5) | JP6490713B2 (fr) |
| KR (1) | KR102402179B1 (fr) |
| CN (3) | CN110317213B (fr) |
| AP (1) | AP2016009383A0 (fr) |
| AU (2) | AU2015209239C1 (fr) |
| CA (1) | CA2936079C (fr) |
| CL (1) | CL2016001876A1 (fr) |
| CY (3) | CY1121850T1 (fr) |
| DK (3) | DK3636649T3 (fr) |
| EA (2) | EA031863B1 (fr) |
| ES (3) | ES2933350T3 (fr) |
| FI (2) | FI3636649T3 (fr) |
| FR (1) | FR25C1013I2 (fr) |
| HR (3) | HRP20240503T1 (fr) |
| HU (4) | HUE060554T2 (fr) |
| IL (2) | IL246860B (fr) |
| LT (4) | LT3097107T (fr) |
| MX (2) | MX392904B (fr) |
| MY (1) | MY193524A (fr) |
| NL (1) | NL301322I2 (fr) |
| NO (1) | NO2025015I1 (fr) |
| NZ (2) | NZ722375A (fr) |
| PE (1) | PE20160931A1 (fr) |
| PH (1) | PH12016501463A1 (fr) |
| PL (3) | PL3636649T3 (fr) |
| PT (3) | PT3572416T (fr) |
| RS (3) | RS63829B1 (fr) |
| SG (2) | SG11201605929RA (fr) |
| SI (3) | SI3097107T1 (fr) |
| SM (3) | SMT202300008T1 (fr) |
| UA (1) | UA121206C2 (fr) |
| WO (1) | WO2015112806A2 (fr) |
| ZA (2) | ZA201604654B (fr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033941A1 (fr) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ME03376B (fr) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Composés macrocycliques comme inhibiteurs de la kinase trk |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| CN113354649B (zh) | 2014-11-16 | 2024-12-10 | 阵列生物制药公司 | 一种新的晶型 |
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| HK1253093A1 (zh) | 2015-06-01 | 2019-06-06 | Loxo Oncology Inc. | 诊断和治疗癌症的方法 |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2765181C2 (ru) | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| PT3733187T (pt) | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| EP3368039A1 (fr) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées |
| WO2017106505A1 (fr) * | 2015-12-15 | 2017-06-22 | University Of South Florida | Composés de fixation de gas5, formulations et utilisations de ceux-ci |
| AU2017246547B2 (en) | 2016-04-04 | 2023-02-23 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| FI3439662T3 (fi) | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| EP3458456B1 (fr) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Préparation de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10689400B2 (en) * | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
| WO2018136661A1 (fr) | 2017-01-18 | 2018-07-26 | Andrews Steven W | Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN107586796B (zh) * | 2017-07-20 | 2021-08-06 | 暨明医药科技（苏州）有限公司 | (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法 |
| CN111182903A (zh) * | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019084285A1 (fr) | 2017-10-26 | 2019-05-02 | Qian Zhao | Formulations d'un inhibiteur de kinase trk macrocyclique |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| AU2018364938B2 (en) * | 2017-11-10 | 2021-11-11 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as TRK kinase inhibitors and uses thereof |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| US20210087206A1 (en) | 2017-12-19 | 2021-03-25 | Turning Point Therapeutics, Inc. | Macrocyclic kinase inhibitors and their use |
| EP3730492A4 (fr) * | 2017-12-22 | 2021-08-11 | Shenzhen TargetRx, Inc. | Composé pyrazolo[1,5-a]pyrimidine substitué, composition pharmaceutique et utilisation associée |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| EP3740490A1 (fr) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Composés de pyrazolo[3,4-d]pyrimidine substitués utilisés en tant qu'inhibiteurs de la kinase ret |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| US11345703B2 (en) | 2018-01-23 | 2022-05-31 | Shenzhen Targetrx, Inc. | Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound |
| TW201932472A (zh) * | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| WO2019184955A1 (fr) * | 2018-03-28 | 2019-10-03 | Fochon Pharmaceuticals, Ltd. | Composés macrocycliques en tant qu'inhibiteurs de kinases trk |
| WO2019191659A1 (fr) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Traitement de cancers associés à trk |
| WO2019201131A1 (fr) * | 2018-04-16 | 2019-10-24 | 深圳市塔吉瑞生物医药有限公司 | Composé macrocyclique di(hétéro)aryle pour inhiber l'activité de la protéine kinase |
| CN111902417B (zh) * | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| WO2019210835A1 (fr) * | 2018-05-04 | 2019-11-07 | 正大天晴药业集团股份有限公司 | Composé macrocyclique de diaryle en tant que modulateur de protéine kinase |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| CN110950889B (zh) * | 2018-09-27 | 2022-04-05 | 北京赛林泰医药技术有限公司 | 一种多靶点激酶抑制剂及其制备方法和用途 |
| EP3858834A4 (fr) * | 2018-09-29 | 2022-06-22 | Shandong Luye Pharmaceutical Co., Ltd. | Dérivé de pyrazolopyrimidine en tant qu'inhibiteur de trk sélectif |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| WO2020094112A1 (fr) * | 2018-11-09 | 2020-05-14 | 山东轩竹医药科技有限公司 | Inhibiteur de la tyrosine kinase macrocyclique et son application |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| US12157741B2 (en) * | 2018-11-19 | 2024-12-03 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of DYRK1A |
| EP3898626A1 (fr) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| CN111592541B (zh) * | 2019-02-21 | 2021-09-10 | 山东轩竹医药科技有限公司 | 大环类激酶抑制剂及其用途 |
| CA3132632A1 (fr) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Inhibiteurs de tyk2 et leurs utilisations |
| CA3134814A1 (fr) * | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Ligands de pseudokinase tyk2 |
| WO2020233645A1 (fr) * | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | Dérivés de macrolides, leur procédé de préparation et leur application |
| WO2020257169A1 (fr) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Polymorphes d'un inhibiteur de kinases macrocycliques |
| WO2020257165A1 (fr) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles destinés à être utilisés dans le traitement d'une maladie |
| WO2020257189A1 (fr) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles pour le traitement d'une maladie |
| MA56505A (fr) * | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | Inhibiteurs macrocycliques de mcl-1 |
| CN112110938B (zh) * | 2019-06-21 | 2021-11-09 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
| CN114127061A (zh) | 2019-07-16 | 2022-03-01 | 迈奥卡迪亚公司 | (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 |
| WO2021027503A1 (fr) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | Composé tricyclique, procédé de préparation, intermédiaire et utilisation associés |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| BR112022010278A2 (pt) * | 2019-11-27 | 2022-10-04 | Turning Point Therapeutics Inc | Terapia combinada que envolve compostos macrocíclicos de diarila |
| MX2022006366A (es) | 2019-11-27 | 2022-06-22 | Turning Point Therapeutics Inc | Terapia de combinacion que implica compuestos de diarilo macrociclico. |
| US11634433B2 (en) * | 2019-12-03 | 2023-04-25 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| US20230101747A1 (en) | 2019-12-06 | 2023-03-30 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| IL294214B2 (en) | 2019-12-27 | 2026-04-01 | Schrodinger Inc | Cyclic compounds and methods for using them |
| CN113045587A (zh) * | 2019-12-27 | 2021-06-29 | 成都倍特药业股份有限公司 | 一种大环结构化合物的晶型及其制备方法 |
| CN113135938B (zh) * | 2020-01-19 | 2022-06-14 | 山东轩竹医药科技有限公司 | 取代的大环类酪氨酸激酶抑制剂及其用途 |
| EP4114530A4 (fr) * | 2020-03-02 | 2024-04-17 | Turning Point Therapeutics, Inc. | Utilisations thérapeutiques de composés macrocycliques |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| JP7495035B2 (ja) * | 2020-05-08 | 2024-06-04 | シュエンジュウ バイオファーマシューティカル カンパニー リミテッド | 大環類チロシンキナーゼ阻害剤の結晶形及びその製造方法 |
| EP4163283A1 (fr) * | 2020-06-04 | 2023-04-12 | Scinnohub Pharmaceutical Co., Ltd | Composé ayant une structure macrocyclique et son utilisation |
| EP4178958A4 (fr) * | 2020-07-10 | 2024-12-11 | Blossomhill Therapeutics, Inc. | Macrocycles et leur utilisation |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| EP4284804A1 (fr) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Composés tricycliques utiles dans le traitement du cancer, des troubles auto-immuns et des troubles inflammatoires |
| WO2022182845A1 (fr) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles et leur utilisation |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113754657B (zh) * | 2021-09-22 | 2023-01-17 | 广州白云山医药集团股份有限公司白云山制药总厂 | 大环类化合物的晶型及其制备方法和应用 |
| CN116063326B (zh) * | 2021-11-02 | 2025-08-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| CN116514813A (zh) * | 2021-12-31 | 2023-08-01 | 轩竹生物科技股份有限公司 | 酪氨酸激酶抑制剂及其中间体的制备方法 |
| AU2023204770A1 (en) * | 2022-01-05 | 2024-07-18 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and use as kinase inhibitors |
| CN115746023B (zh) * | 2022-10-27 | 2024-08-09 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
| WO2025059027A1 (fr) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Dérivés de cyclopenta[e]pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de malt1 |
| CN121399134A (zh) * | 2023-10-10 | 2026-01-23 | 上海翊维康医药有限责任公司 | 新的i型拓扑异构酶抑制剂及其制备方法和用途 |
| WO2025217347A2 (fr) | 2024-04-11 | 2025-10-16 | Bristol-Myers Squibb Company | Procédé de préparation de repotrectinib |
| WO2025235733A1 (fr) * | 2024-05-09 | 2025-11-13 | Blossomhill Therapeutics, Inc. | Macrocycles bis-bicyclohétéroaryle et leur utilisation |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| EP0281841B1 (fr) | 1987-03-07 | 1990-11-14 | Bayer Ag | Procédé de préparation d'amino-5 dihalogéno-4,6 pyridines |
| ATE195935T1 (de) | 1993-03-25 | 2000-09-15 | Upjohn Co | Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung |
| PT657458E (pt) | 1993-12-07 | 2002-02-28 | Lilly Co Eli | Inibidores de proteina cinase c |
| FR2746309B1 (fr) | 1996-03-22 | 1998-04-17 | Oreal | Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| FR2793791B1 (fr) | 1999-05-19 | 2002-01-25 | Univ Paris 7 Denis Diderot | Nouveaux composes inhibiteurs specifiques de phospholipases a2 |
| JP4180365B2 (ja) | 2000-07-31 | 2008-11-12 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジン誘導体 |
| ATE301661T1 (de) | 2000-12-08 | 2005-08-15 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
| JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| US7970766B1 (en) | 2007-07-23 | 2011-06-28 | Google Inc. | Entity type assignment |
| KR20110073500A (ko) * | 2008-09-08 | 2011-06-29 | 메르크 파텐트 게엠베하 | 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘 |
| WO2010033941A1 (fr) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| EP2348860B1 (fr) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Composés inhibiteurs de jak à la pyrazolopyrimidine et procédés |
| WO2010063487A1 (fr) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament |
| WO2010086040A1 (fr) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines pour traitement de la myopathie de duchenne |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US20110029480A1 (en) * | 2009-08-03 | 2011-02-03 | IntelliCubes, Inc. | Method of Compiling Multiple Data Sources into One Dataset |
| ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
| WO2011071716A1 (fr) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Composés hétérocycliques contenant un cœur indole |
| WO2011071725A1 (fr) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Composés hétérocycliques contenant un cœur pyrrolopyridine ou benzimidazole |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| ME03376B (fr) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Composés macrocycliques comme inhibiteurs de la kinase trk |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
| WO2012075393A2 (fr) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activateurs de la dégradation protéasomique et leurs utilisations |
| EP2508607A1 (fr) * | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (fr) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Composés macrocycliques et leur utilisation en tant qu'inhibiteurs de cdk8 |
| BR112014003802A2 (pt) * | 2011-08-19 | 2017-06-13 | Merck Sharp & Dohme | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento |
| WO2013045701A2 (fr) | 2011-09-29 | 2013-04-04 | L'oreal | Procédé de coloration utilisant une composition comprenant un composé iridoïde glycosylique et un nucléophile ou un polymère aminé ou thiolé et composition et dispositifs s'y rapportant |
| WO2013045702A2 (fr) | 2011-09-29 | 2013-04-04 | L'oreal | Colorant comprenant un composé iridoïde non glycosyle et un nucléophile ou un amino ou thio polymère, procédé de coloration et dispositif afférent |
| BR112014007622A2 (pt) | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
| GB2495134B (en) | 2011-09-30 | 2014-06-11 | Tridonic Uk Ltd | Power supply apparatus |
| JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| DK2822953T5 (en) | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| WO2013134219A1 (fr) * | 2012-03-09 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Composés à base d'imidazo [1, 2-b] pyridazine, compositions les comprenant et utilisations de ceux-ci |
| CN104302649B (zh) | 2012-03-09 | 2017-06-23 | 莱西肯医药有限公司 | 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 |
| EP2645540A1 (fr) | 2012-03-28 | 2013-10-02 | Siemens Aktiengesellschaft | Matériau anti-effluves pour une machine électrique |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| JP2016506921A (ja) | 2013-01-30 | 2016-03-07 | バイエル ファーマ アクチエンゲゼルシャフト | アミノ置換イソチアゾール |
| WO2014173928A1 (fr) | 2013-04-23 | 2014-10-30 | Lek Pharmaceuticals D.D. | Nouveau procédé de synthèse de 8-chloro-1-méthyl-benzo[d]azépine, nouveaux intermédiaires et leur production |
| JPWO2015012328A1 (ja) | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015073267A1 (fr) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Composés hétéroaryle substitués et méthodes d'utilisation |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| WO2016070241A1 (fr) | 2014-11-03 | 2016-05-12 | Ctxt Pty Ltd | Composés de triazine, compositions et synthèse |
| CA2971024C (fr) | 2014-12-15 | 2023-09-26 | Handok Inc. | Composes d'heteroaryle a cycle condense et leur utilisation a titre d'inhibiteurs de trk |
| JP6800158B2 (ja) | 2015-02-20 | 2020-12-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
| BR112017023764A2 (pt) | 2015-05-05 | 2018-07-31 | Bayer Pharma AG | derivados de ciclohexano substituído por amido |
| US10894131B2 (en) | 2015-06-29 | 2021-01-19 | Q-Core Medical Ltd. | Methods circuits devices assemblies systems and associated computer executable code for sensing and analyzing fluid characteristics within a conduit of a medical device and air bubbles |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2765181C2 (ru) | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| PT3733187T (pt) | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| EP3368039A1 (fr) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées |
| US11596639B2 (en) | 2016-03-04 | 2023-03-07 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| JP2020533269A (ja) | 2016-12-14 | 2020-11-19 | デベロップメント センター フォー バイオテクノロジー | 抗体−薬物複合体およびその使用 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN111182903A (zh) | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
-
2015
- 2015-01-23 ES ES19169041T patent/ES2933350T3/es active Active
- 2015-01-23 SG SG11201605929RA patent/SG11201605929RA/en unknown
- 2015-01-23 SM SM20230008T patent/SMT202300008T1/it unknown
- 2015-01-23 SI SI201530810T patent/SI3097107T1/sl unknown
- 2015-01-23 PE PE2016000959A patent/PE20160931A1/es unknown
- 2015-01-23 CA CA2936079A patent/CA2936079C/fr active Active
- 2015-01-23 ES ES19212110T patent/ES2976459T3/es active Active
- 2015-01-23 LT LTEP15740510.1T patent/LT3097107T/lt unknown
- 2015-01-23 MY MYPI2016001385A patent/MY193524A/en unknown
- 2015-01-23 DK DK19212110.1T patent/DK3636649T3/da active
- 2015-01-23 HU HUE19169041A patent/HUE060554T2/hu unknown
- 2015-01-23 SM SM20190388T patent/SMT201900388T1/it unknown
- 2015-01-23 EP EP19212126.7A patent/EP3636650A1/fr not_active Withdrawn
- 2015-01-23 PL PL19212110.1T patent/PL3636649T3/pl unknown
- 2015-01-23 US US15/113,583 patent/US9714258B2/en not_active Ceased
- 2015-01-23 CN CN201910549014.1A patent/CN110317213B/zh active Active
- 2015-01-23 RS RS20221161A patent/RS63829B1/sr unknown
- 2015-01-23 ES ES15740510T patent/ES2735729T3/es active Active
- 2015-01-23 LT LTEP19169041.1T patent/LT3572416T/lt unknown
- 2015-01-23 NZ NZ722375A patent/NZ722375A/en unknown
- 2015-01-23 HU HUE19212110A patent/HUE066590T2/hu unknown
- 2015-01-23 EP EP19212110.1A patent/EP3636649B1/fr active Active
- 2015-01-23 WO PCT/US2015/012597 patent/WO2015112806A2/fr not_active Ceased
- 2015-01-23 JP JP2016566857A patent/JP6490713B2/ja active Active
- 2015-01-23 EA EA201691492A patent/EA031863B1/ru active IP Right Revival
- 2015-01-23 NZ NZ761094A patent/NZ761094A/en unknown
- 2015-01-23 HR HRP20240503TT patent/HRP20240503T1/hr unknown
- 2015-01-23 PT PT191690411T patent/PT3572416T/pt unknown
- 2015-01-23 SI SI201531994T patent/SI3636649T1/sl unknown
- 2015-01-23 EP EP19169041.1A patent/EP3572416B1/fr active Active
- 2015-01-23 HR HRP20191283TT patent/HRP20191283T1/hr unknown
- 2015-01-23 RS RS20240447A patent/RS65417B1/sr unknown
- 2015-01-23 EP EP19212106.9A patent/EP3636648A1/fr not_active Withdrawn
- 2015-01-23 SG SG10202000191YA patent/SG10202000191YA/en unknown
- 2015-01-23 KR KR1020167020188A patent/KR102402179B1/ko active Active
- 2015-01-23 PL PL15740510T patent/PL3097107T3/pl unknown
- 2015-01-23 UA UAA201608991A patent/UA121206C2/uk unknown
- 2015-01-23 AU AU2015209239A patent/AU2015209239C1/en active Active
- 2015-01-23 MX MX2020001360A patent/MX392904B/es unknown
- 2015-01-23 SI SI201531908T patent/SI3572416T1/sl unknown
- 2015-01-23 EP EP15740510.1A patent/EP3097107B1/fr active Active
- 2015-01-23 LT LTEP19212110.1T patent/LT3636649T/lt unknown
- 2015-01-23 MX MX2016009588A patent/MX2016009588A/es active IP Right Grant
- 2015-01-23 SM SM20240175T patent/SMT202400175T1/it unknown
- 2015-01-23 EP EP23220719.1A patent/EP4338739A3/fr active Pending
- 2015-01-23 PT PT192121101T patent/PT3636649T/pt unknown
- 2015-01-23 DK DK15740510.1T patent/DK3097107T3/da active
- 2015-01-23 PL PL19169041.1T patent/PL3572416T3/pl unknown
- 2015-01-23 HU HUE15740510A patent/HUE045208T2/hu unknown
- 2015-01-23 CN CN201580005705.5A patent/CN106170289B/zh active Active
- 2015-01-23 HR HRP20221518TT patent/HRP20221518T1/hr unknown
- 2015-01-23 US US18/147,888 patent/USRE50634E1/en active Active
- 2015-01-23 RS RS20190900A patent/RS59059B1/sr unknown
- 2015-01-23 DK DK19169041.1T patent/DK3572416T3/da active
- 2015-01-23 AP AP2016009383A patent/AP2016009383A0/en unknown
- 2015-01-23 CN CN201910549748.XA patent/CN110317214B/zh active Active
- 2015-01-23 EA EA201892241A patent/EA201892241A1/ru unknown
- 2015-01-23 PT PT15740510T patent/PT3097107T/pt unknown
- 2015-01-23 FI FIEP19212110.1T patent/FI3636649T3/fi active
-
2016
- 2016-07-07 ZA ZA2016/04654A patent/ZA201604654B/en unknown
- 2016-07-20 IL IL246860A patent/IL246860B/en active IP Right Grant
- 2016-07-22 CL CL2016001876A patent/CL2016001876A1/es unknown
- 2016-07-25 PH PH12016501463A patent/PH12016501463A1/en unknown
-
2017
- 2017-05-31 US US15/609,962 patent/US10246466B2/en active Active
-
2018
- 2018-11-29 US US16/204,566 patent/US10618912B2/en active Active
-
2019
- 2019-02-27 JP JP2019034652A patent/JP2019104748A/ja not_active Withdrawn
- 2019-07-17 CY CY20191100764T patent/CY1121850T1/el unknown
- 2019-08-21 IL IL268820A patent/IL268820B/en unknown
- 2019-12-10 AU AU2019279951A patent/AU2019279951B2/en active Active
-
2020
- 2020-02-21 US US16/797,866 patent/US20200216465A1/en not_active Abandoned
- 2020-07-06 ZA ZA2020/04100A patent/ZA202004100B/en unknown
-
2021
- 2021-01-07 JP JP2021001588A patent/JP2021063121A/ja active Pending
- 2021-09-27 US US17/485,942 patent/US20220112213A1/en not_active Abandoned
-
2022
- 2022-07-08 JP JP2022110613A patent/JP7356546B2/ja active Active
- 2022-12-19 CY CY20221100793T patent/CY1125786T1/el unknown
-
2023
- 2023-07-28 US US18/227,561 patent/US12404281B2/en active Active
- 2023-09-22 JP JP2023158350A patent/JP2023179539A/ja not_active Ceased
-
2025
- 2025-03-10 CY CY2025009C patent/CY2025009I1/el unknown
- 2025-03-12 NL NL301322C patent/NL301322I2/nl unknown
- 2025-03-13 NO NO2025015C patent/NO2025015I1/no unknown
- 2025-03-20 HU HUS2500016C patent/HUS2500016I1/hu unknown
- 2025-03-20 FI FIC20250015C patent/FIC20250015I1/fi unknown
- 2025-04-08 LT LTPA2025513C patent/LTPA2025513I1/lt unknown
- 2025-04-09 FR FR25C1013C patent/FR25C1013I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500016I1 (hu) | Diaril-makrociklusok mint proteinkináz-modulátorok | |
| IL256377A (en) | Diaryl chiral macrocycles as protein kinase modulators | |
| IL259421B (en) | ror - gamma modulators | |
| IL258013A (en) | Modulators of kras expression | |
| IL252417B (en) | Use of erythrohydroxybupropion to increase plasma drug level | |
| IL262381A (en) | 6-Aminopyridin-3-yl thiazoles as ror-gamma-t modulators | |
| EP3178923A4 (fr) | Utilisation d'une protéine susd2 à titre de marqueur | |
| IL247234A0 (en) | Caspase-6 modulators | |
| GB201620640D0 (en) | Vacuum-deposited modification of polymer surfaces | |
| EP3200955A4 (fr) | Procédés de polissage | |
| SG11201607445QA (en) | Methods of modulating wars2 | |
| PT3377106T (pt) | Modulação da ciliogénese | |
| GB201418230D0 (en) | Construction of surfaces | |
| GB201407888D0 (en) | Novel specific kinase modulators | |
| GB201406276D0 (en) | Making of land |